Impact of Adverse Drug Reactions in Patients with End Stage Renal Disease in Greece

Marios Spanakis, Marianna Roubedaki, Ioannis Tzanakis, Michail Zografakis-Sfakianakis, Evridiki Patelarou and Athina Patelarou
Additional contact information
Marios Spanakis: Department of Nursing, Faculty of Health Sciences, Hellenic Mediterranean University, Estavromenos, GR-71140 Heraklion, Crete, Greece
Marianna Roubedaki: Department of Nephrology, General Hospital of Chania, Meletiou Metaxaki 25, GR-73131 Chania, Crete, Greece
Ioannis Tzanakis: Department of Nephrology, General Hospital of Chania, Meletiou Metaxaki 25, GR-73131 Chania, Crete, Greece
Michail Zografakis-Sfakianakis: Department of Nursing, Faculty of Health Sciences, Hellenic Mediterranean University, Estavromenos, GR-71140 Heraklion, Crete, Greece
Evridiki Patelarou: Department of Nursing, Faculty of Health Sciences, Hellenic Mediterranean University, Estavromenos, GR-71140 Heraklion, Crete, Greece
Athina Patelarou: Department of Nursing, Faculty of Health Sciences, Hellenic Mediterranean University, Estavromenos, GR-71140 Heraklion, Crete, Greece

IJERPH, 2020, vol. 17, issue 23, 1-17

Abstract: Background: Patients with end-stage renal disease (ESRD) require specialized therapeutic interventions. The decreased renal function that modulates the physiology and presence of comorbidities is often associated with variations in the pharmacological response, thus increasing the risk of adverse drug events or reactions (ADE/ADRs) from co-administered drugs. Methods: A cross-sectional study to record comorbidities, drug–drug interactions (DDIs), ADE/ADRs in patients with chronic kidney disease of stage five in Greece. The study enrolled 60 patients of mean age 64.8 ± 12.9 years, undergoing hemodialysis three times a week. Demographic and social factors, comorbidities, laboratory test data, medication regimens, DDIs and the reporting of ADE/ADRs were analyzed. Results: Cardiovascular diseases and diabetes were the main comorbidities. In total, 50 different DDIs of various clinical significance were identified. CNS, GI-track, and musculoskeletal-system-related ADE/ADRs were most often reported by patients. ADE/ADRs as clinical outcome from DDIs were associated in 64% of the total identified DDIs. There was a positive trend between number of medications, ADE/ADRs report and DDIs. Conclusions: The impact of ADE/ADRs in ESRD patients should be always considered. Guidelines as well as continuous training in the context of evidence-based clinical practice by healthcare personnel on therapy administration and prevention of adverse events are important.

Keywords: chronic kidney disease; end-stage renal disease; adverse drug reactions; drug–drug interactions; quality of life; chronic disease (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/23/9101/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/23/9101/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:23:p:9101-:d:457585

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().